Picture of IDEXX Laboratories logo

IDXX — IDEXX Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Veterinary diagnostics maker IDEXX raises annual profit forecast on pet healthcare testing demand

Veterinary diagnostics maker IDEXX raises annual profit forecast on pet healthcare testing demand

- IDEXX Laboratories IDXX.O raised its annual profit forecast on Tuesday after reporting better-than-expected second-quarter results on steady pet healthcare diagnostics demand and higher testing volumes at veterinary clinics.

Its shares rose about 3% in premarket trading.


Here are the details:


  • IDEXX raised its 2026 profit forecast to $14.69 to $14.94 per share from $14.45 to $14.90 per share previously. The midpoint of the new range is about $14.82, above analysts' estimate of $14.65, according to data compiled by LSEG.

  • CEO Mike Erickson said innovation across the company's veterinary diagnostic platforms, including its in-clinic testing platform IDEXX inVue Dx, supported greater customer adoption and diagnostic utilization.

  • It narrowed its annual revenue forecast to $4.70 billion to $4.75 billion from $4.68 billion to $4.76 billion previously, lifting the midpoint by $5 million to about $4.72 billion despite a $15 million foreign exchange headwind. The midpoint is slightly above analysts' estimate of $4.71 billion.

  • Companion Animal Group revenue, IDEXX's largest segment, grew 9% to $1.12 billion from a year earlier and topped analysts' estimate of $1.10 billion.

  • Water revenue rose 15% to $58.6 million, while Livestock, Poultry and Dairy revenue increased 11% to $35.2 million.

  • IDEXX said its inVue Dx in-clinic diagnostic analyzer installed base exceeded 9,000 systems after more than 1,600 placements during the quarter.

  • Second-quarter revenue rose 10% to $1.22 billion, topping analysts' estimate of $1.20 billion, while adjusted profit of $4.27 exceeded an expectation of $3.94.


(Reporting by Sahil Pandey in Bengaluru; Editing by Pooja Desai)

((Sahil.Pandey@thomsonreuters.com;))

Recent news on IDEXX Laboratories

See all news